CG
CBMG

Cutler Group’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Cutler Group’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-300
Closed -$5K – 4969
2018
Q2 		$5K Sell
300
-300
-50% -$5.62K ﹤0.01% 3180
2018
Q1 		$10K Buy
+600
New +$11K ﹤0.01% 2823

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cutler Group's CBMG Position: Q3 2018 in Review

Cutler Group sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q3 2018, closing a stake of 300 shares — an estimated $5K sold.

Cutler Group first reported a position in CBMG in Q1 2018 and held it in 2 quarters. The position peaked at $10K in Q1 2018. 38 funds tracked by Wall St. Rank hold CBMG as of Q3 2018.

  • Cutler Group reported no remaining Cellular Biomedicine Group, Inc. position as of Q3 2018 after selling out during the quarter.
  • Cutler Group sold 300 Cellular Biomedicine Group, Inc. shares in Q3 2018, an estimated $5K.
  • Cutler Group first reported a position in Cellular Biomedicine Group, Inc. in Q1 2018 and held it in 2 quarters.
  • Cutler Group's Cellular Biomedicine Group, Inc. position peaked at $10K in Q1 2018.
  • 38 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q3 2018.

Based on Cutler Group's 13F filing for Q3 2018, filed 7 Nov 2018.